Answers are grounded in this paper and cite their sources.
Research demonstrates SFRP2's role in worsening kidney disease in diabetes, suggesting new treatment avenues.
SFRP2 drives renal cholesterol accumulation in DKD through the CN/ATF3/HDAC1/CH25H signaling axis, and therapeutic strategies targeting 25-HC restoration or SREBP2 inhibition show promise for DKD treatment.
No takes yet. Share an insight, caveat, or question.
Lv et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: